BioStock: Elicera Therapeutics keeps strong momentum after IPO

Since its successful IPO on the Nasdaq First North Growth Market in June, Elicera Therapeutics has been advancing with all four of its cancer cell therapy projects. During Q3, one of the key highlights for the company has been the presentation of preclinical Proof-of-Concept data with its patented iTANK platform for the optimisation of CAR T-cell therapies. Since the period, Elicera has entered a collaboration with German gene therapy CDMO BioNTech for Elicera’s ELC-401 project. BioStock takes a closer look.

Read the article at biostock.se:

https://www.biostock.se/en/2021/11/elicera-therapeutics-keeps-strong-momentum-after-ipo/

This is a press release from BioStock - Connecting Innovation & Capital.https://www.biostock.se